See more : CDL Hospitality Trusts (CDHSF) Income Statement Analysis – Financial Results
Complete financial analysis of Prothena Corporation plc (PRTA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Prothena Corporation plc, a leading company in the Biotechnology industry within the Healthcare sector.
- Zhenro Properties Group Limited (6158.HK) Income Statement Analysis – Financial Results
- Chinney Alliance Group Limited (0385.HK) Income Statement Analysis – Financial Results
- Top Union Electronics Corp. (6266.TWO) Income Statement Analysis – Financial Results
- Riverview Acquisition Corp. (RVAC) Income Statement Analysis – Financial Results
- Affiliated Resources Corp (AFFL) Income Statement Analysis – Financial Results
Prothena Corporation plc (PRTA)
About Prothena Corporation plc
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 91.37M | 53.91M | 200.58M | 853.00K | 814.00K | 955.00K | 27.52M | 1.06M | 1.61M | 50.85M | 676.00K | 2.66M | 507.00K | 1.24M |
| Cost of Revenue | 220.57M | 6.74M | 82.28M | 74.88M | 50.84M | 101.18M | 134.55M | 119.53M | 58.44M | 38.45M | 26.05M | 34.14M | 0.00 | 0.00 |
| Gross Profit | -129.20M | 47.16M | 118.29M | -74.03M | -50.02M | -100.23M | -107.03M | -118.48M | -56.83M | 12.40M | -25.38M | -31.48M | 507.00K | 1.24M |
| Gross Profit Ratio | -141.40% | 87.49% | 58.98% | -8,678.90% | -6,145.21% | -10,495.08% | -388.92% | -11,230.24% | -3,536.53% | 24.39% | -3,753.85% | -1,184.39% | 100.00% | 100.00% |
| Research & Development | 220.57M | 135.56M | 82.28M | 74.88M | 50.84M | 101.18M | 134.55M | 119.53M | 58.44M | 38.45M | 26.05M | 34.14M | 24.17M | 9.79M |
| General & Administrative | 61.84M | 49.90M | 46.32M | 38.70M | 35.74M | 42.48M | 48.23M | 41.06M | 23.11M | 19.05M | 15.05M | 9.93M | 5.58M | 3.62M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 61.84M | 49.90M | 46.32M | 38.70M | 35.74M | 42.48M | 48.23M | 41.06M | 23.11M | 19.05M | 15.05M | 9.93M | 5.58M | 3.62M |
| Other Expenses | 0.00 | 5.95M | -54.00K | 1.31M | 8.40M | 2.74M | -2.35M | 571.00K | 26.00K | 310.00K | -225.00K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 282.41M | 185.46M | 128.60M | 113.59M | 86.57M | 143.67M | 182.77M | 160.59M | 81.54M | 57.50M | 41.10M | 44.07M | 29.75M | 13.41M |
| Cost & Expenses | 282.41M | 185.46M | 128.60M | 113.59M | 86.57M | 143.67M | 182.77M | 160.59M | 81.54M | 57.50M | 41.10M | 44.07M | 29.75M | 13.41M |
| Interest Income | 31.01M | 6.35M | 42.00K | 1.37M | 8.20M | 6.39M | 3.55M | 0.00 | 196.00K | 79.00K | 71.00K | 5.00K | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 8.20M | 3.70M | 3.69M | 0.00 | 0.00 | 0.00 | 154.00K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 928.00K | 6.74M | 6.80M | 6.98M | 6.82M | 3.22M | 3.07M | 2.43M | 806.00K | 743.00K | 660.00K | 468.00K | 391.00K | 191.00K |
| EBITDA | -190.11M | -131.56M | 71.98M | -111.22M | -78.94M | -152.90M | -152.19M | -156.54M | -79.13M | -5.91M | -39.77M | -40.94M | -28.85M | -11.97M |
| EBITDA Ratio | -208.06% | -244.05% | 35.88% | -13,216.18% | -10,542.87% | -13,252.88% | -564.17% | -15,121.80% | -4,974.30% | -13.07% | -5,980.33% | -1,557.94% | -5,690.93% | -963.07% |
| Operating Income | -191.04M | -131.56M | 71.98M | -112.73M | -85.70M | -158.86M | -155.25M | -159.54M | -79.94M | -6.65M | -40.43M | -41.41M | -29.24M | -12.16M |
| Operating Income Ratio | -209.08% | -244.05% | 35.88% | -13,216.18% | -10,527.89% | -16,634.03% | -564.17% | -15,121.80% | -4,974.30% | -13.07% | -5,980.33% | -1,557.94% | -5,768.05% | -978.44% |
| Total Other Income/Expenses | 30.56M | 5.95M | -54.00K | 1.31M | 8.40M | 2.74M | -2.35M | 571.00K | 26.00K | 310.00K | -154.00K | 5.00K | 0.00 | 0.00 |
| Income Before Tax | -160.48M | -125.61M | 71.92M | -111.43M | -77.30M | -156.12M | -157.60M | -158.96M | -79.91M | -6.34M | -40.58M | -41.41M | -29.24M | -12.16M |
| Income Before Tax Ratio | -175.64% | -233.01% | 35.86% | -13,062.95% | -9,496.07% | -16,347.12% | -572.71% | -15,067.68% | -4,972.68% | -12.47% | -6,003.11% | -1,557.75% | -5,768.05% | -978.44% |
| Income Tax Expense | -13.45M | -8.66M | 4.95M | -283.00K | 379.00K | -470.00K | -4.37M | 1.14M | 701.00K | 811.00K | 415.00K | 6.00K | 426.00K | 320.00K |
| Net Income | -147.03M | -116.95M | 66.98M | -111.14M | -77.68M | -155.65M | -153.24M | -160.11M | -80.61M | -7.15M | -41.00M | -41.41M | -29.67M | -12.48M |
| Net Income Ratio | -160.91% | -216.95% | 33.39% | -13,029.78% | -9,542.63% | -16,297.91% | -556.84% | -15,176.11% | -5,016.30% | -14.06% | -6,064.50% | -1,557.98% | -5,852.07% | -1,004.18% |
| EPS | -2.76 | -2.47 | 1.51 | -2.78 | -1.95 | -3.93 | -4.07 | -4.66 | -2.66 | -0.29 | -2.20 | -2.84 | -1.68 | -0.71 |
| EPS Diluted | -2.76 | -2.47 | 1.38 | -2.78 | -1.95 | -3.93 | -4.07 | -4.66 | -2.66 | -0.29 | -2.20 | -2.84 | -1.68 | -0.71 |
| Weighted Avg Shares Out | 53.22M | 47.37M | 44.23M | 39.92M | 39.88M | 39.56M | 37.65M | 34.35M | 30.33M | 24.67M | 18.62M | 14.59M | 17.68M | 17.68M |
| Weighted Avg Shares Out (Dil) | 53.22M | 47.37M | 48.46M | 39.92M | 39.88M | 39.56M | 37.65M | 34.35M | 30.33M | 24.67M | 18.62M | 14.59M | 17.68M | 17.68M |
Prothena Provides Updates on PRX012, PRX123, Birtamimab and Portfolio Programs
Alzheimer's Disease Space Evolves in 2023: Stocks in Focus
Prothena (PRTA) Pipeline Shows Promise in a Tough AD Market
Prothena (PRTA) Q3 Earnings Beat on Collaboration Revenue Hike
Prothena (PRTA) Beats Q3 Earnings and Revenue Estimates
Prothena to Report Third Quarter 2023 Financial Results on November 2
Biogen Pulls Prothena Into A Steep Dive On Mixed Results For Alzheimer's Treatment
Prothena (PRTA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
5 Biotech Stocks Set to Outpace Q3 Earnings Estimates
Prothena (PRTA) Soars 18.7%: Is Further Upside Left in the Stock?
Source: https://incomestatements.info
Category: Stock Reports